The VerdictHIGH CONVICTION

Most of your annual blood panel doesn't help you live longer.

Tonight, write down the five tests worth asking for at your next blood draw: a cholesterol (lipid) panel, blood sugar, blood pressure, kidney function, and Lp(a) once in your life. Bring the list. Don't let the lab pick the menu.

The number that changed my mind: across randomized trials of about 250,000 adults, getting a full annual check-up didn't help people live any longer.
What most people get wrong: more tests feels more thorough, but each extra test mostly adds false alarms, not earlier saves.
Start here: ask for five tests that actually earn their place — a cholesterol panel, blood sugar, blood pressure, kidney function, and a one-time Lp(a) — and skip the rest.

Think of a blood panel like smoke alarms. Five placed where fires actually start — the kitchen, the wiring — catch real danger early. Wire up forty through the whole house and most of what goes off is burnt toast: false alarms that send you running with nothing wrong. More alarms isn't more safety. It's more noise.

Longevity & Health Markers · The Verdict

Bloodwork Basics: What to Test Annually

Most of your annual blood panel doesn't help you live longer. Five tests do.

CONVICTION: HIGH

The Practical Takeaway

Ask for the targeted core, not the big panel. A lipid panel with non-HDL-C (free, it's just total minus HDL) and ApoB; fasting glucose or HbA1c; blood pressure at every visit; kidney function (eGFR) and a one-time liver check if you carry risk factors; Lp(a) once in your life.
Use sensible spacing. If results are normal and you're low-risk: lipids every 4 to 6 years, blood sugar every 3 years. Move to yearly only once you're near a treatment threshold or already on medication.
Stop adding tests "while you're at it." Don't bolt thyroid (TSH) or vitamin D onto an asymptomatic panel by default. Don't buy expanded "longevity" arrays expecting them to extend your life.
Treat one odd value as a trend to re-check, not a diagnosis. Confirm anything near a treatment threshold on a proper venous lab draw before acting.

Tonight, write down the five tests worth asking for at your next blood draw: a cholesterol (lipid) panel, blood sugar, blood pressure, kidney function, and Lp(a) once in your life.

Bring that list to the appointment. The default "full panel" bundles in a dozen low-value tests that mostly generate false alarms. You pick the menu, not the lab.

Takes 2 minutes. No equipment needed.

Conviction

HIGH

HIGH overall, per-claim stratified. The load-bearing claims — the bundled annual panel doesn't reduce mortality, a small targeted core is what's evidence-supported, and routine asymptomatic thyroid and vitamin D testing isn't — rest on high-certainty Cochrane evidence and guideline consensus. MODERATE on Lp(a) once-in-a-lifetime and ApoB as the preferred atherogenic measure. LOW on expanded "longevity" panels as an evidence-based annual purchase.

What would change my mind: the broad panel doesn't reduce mortality

A large randomized trial (~20,000 adults, 10+ years of follow-up) showing that a modern targeted panel — lipids with ApoB, HbA1c, blood pressure, kidney function, one-time Lp(a) — acted on with current guideline therapy, cuts all-cause mortality versus usual care, would upgrade the targeted core from "evidence-supported screening" to "proven mortality lever."

What would change my mind: "longevity panels" aren't worth it

A high-quality outcome trial showing that acting on an expanded biomarker array reduces hard endpoints (heart attacks, deaths) beyond what the targeted core delivers would lift the "longevity panel" claim out of LOW.

Go Deeper

Want evidence-scored answers to health questions like this — what's worth testing, taking, and tracking? Join The Verdict for free weekly reviews.

Join The Verdict — Free

Sources

Krogsbøll LT, Jørgensen KJ, Gøtzsche PC, 2019, Cochrane Database of Systematic Reviews (PMID 30699470). 17 RCTs, ~250,000 adults — general health checks had little or no effect on all-cause, cardiovascular, or cancer mortality.
Krogsbøll LT, Jørgensen KJ, Grønhøj Larsen C, Gøtzsche PC, 2012, BMJ (PMID 23169868). 16 RCTs (~182,880 adults) — health checks increased new diagnoses and drug starts without reducing mortality.
Blum MR et al., 2018, J Clin Endocrinol Metab (PMID 29846630) + Moutzouri E et al., 2020, J Gerontol A Biol Sci Med Sci (PMID 32577745). TRUST-nested RCTs — levothyroxine for screen-detected subclinical hypothyroidism did not improve atherosclerosis or fatigability.
Casagrande et al., 2013, Am J Prev Med (PMID 23867023). NHANES, N=7,189 — blood-pressure-triggered diabetes screening caught only ~44% of undiagnosed diabetes.
US Preventive Services Task Force, 2021, JAMA + Canadian Task Force on Preventive Health Care, 2024 — guideline basis for targeted lipid and glucose screening in defined populations and cadences.

Most of your annual blood panel doesn't help you live longer.

Bloodwork Basics: What to Test Annually

The Practical Takeaway

Sources

Get weekly verdicts — no fluff, just evidence

Related free research

There are 424 more inside